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3530 mg prednisolone) resulted in Talaromyces marneffei
infection. Chest computed tomographic scan revealed diffuse
interstitial and multiple cavitary lung lesions. Treatment with
amphotericin B combined with itraconazole resulted in total
recovery, with marked regression of lung lesions.
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p://dx.doi.org/10.1016/j.nmni.2015.06.010A 57-year-old man presented with unproductive cough and
dyspnea for 6 months in Fujian Province, China, on 2 March
2013. He was ﬁrst misdiagnosed as having idiopathic pulmonary
ﬁbrosis because of the diffuse lung lesions observed on chest
computed tomographic (CT) scan (Fig. 1a) and was treated with
a large amount of steroids (accumulated dose equivalent to
3530 mg prednisolone in 54 days). However, his dyspnea
became severe, and he had an unresolved fever during the
post–rainy season conditions present 10 days before he was
admitted to our hospital.
Physical examination at this time revealed tachypnea, slight
cyanosis, respiratory rate of 28 breaths per minute, and a few
ﬁne crepitation rales heard over the lower lobe of each lung.
No other abnormalities were noted, and no skin lesions or
lymphadenopathies were observed. He did not have any heart
disease. Laboratory test results were as follows: serum brain
natriuretic peptide was normal; white blood cell counts were
12.1 × 109/L with 80% neutrophils. Chest CT scan revealed
diffuse interstitial and multiple cavitary lung lesions (Fig. 1b).
Arterial blood gas analysis revealed a low PaO2/FiO2 ratio of
160 mm Hg (pH 7.435, PaCO2 31.4 mm Hg, PaO2 65.6 mm Hg,
HCO3− 21.3 mmol/L under the condition of FiO2 41% oxygen),
suggesting severe adult respiratory distress syndrome. Plasma
HIV antibody and autoimmune antibody tests were negative;
cellular and humoral immunity tests were mostly close to
normal. Although the serum aspergillus galactomannan antigen
assay was normal (enzyme immunoassay), the bronchoalveolar
lavage (BAL) smear showed some intracellular yeastlike cells in
macrophages (Fig. 2a), and fungal cultures of the BAL and blood
samples yielded Talaromyces marneffei (Fig. 2b).
The pathogen’s gene fragment was obtained by PCR ampli-
ﬁcation of 16S RNA of T. marneffei both from sputum and BAL
(PM-F: CTA CAT ATG ATG TCG TAC CGG GCT CCC TT,
PM-R: CAT CTC GAG CAG ACC AGC TTC TTC GCC), and
its DNA sequence by direct sequencing shared 100% homology
with T. marneffei ATCC 18224 (GenBank XM_002148843) and
85% homology with Talaromyces stipitatus ATCC 10500 (Gen-
Bank XM_002485272) from GenBank [1]. Therefore, further
examination of the organism’s DNA sequence was conﬁrmed
as T. marneffei. The patient was provided liposomal ampho-
tericin B (1 mg/kg daily) combined with itraconazole (200 mg/d)
for 18 days with a gradual reduction of the glucocorticoid dose,
followed by itraconazole at a daily oral dose of 200 mg twice a
day as secondary prophylaxis. He experienced dyspnea relief
and recovered gradually. When his oxygenation index excee-
ded 300 mm Hg (Fig. 1c), he was discharged from the hospital.
He has been followed up for 17 months without recurrence, his
SpO2 was 99% under air and his chest CT scan was nearly
normal except for residual ﬁbrosis in both lungs (Fig. 1d).lf of European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
FIG. 1. Diffuse interstitial and multiple cavitary lung lesions due to Talaromyces marneffei infection on computed tomography (CT). (a) Chest CT
revealing interstitial lung lesions at lower lobes of both lungs on 2 February 2013. (b) Chest CT showing progressive diffuse interstitial lung lesions and
novel multiple cavitary lesions (arrow) at all lobes of both lungs on 1 April 2013. (c) Chest CT revealing marked regression of interstitial and cavitary
lung lesions after treatment on 6 May 2013. (d) Chest CT showing near-normal ﬁndings except for residual ﬁbrosis in both lungs after 5 months’
follow-up on 9 September 2013.
NMNI Li et al. Lung lesions due to T. marneffei 15Talaromyces marneffei is an emerging dimorphic human path-
ogenic fungus endemic to Southeast Asian areas such as India,
Southeast China and Taiwan [2,3]. Most disseminated T. marneffei
infections have been diagnosed in HIV-related patients [4], and
some have also been found in immunosuppressed patients [5].
The case described here occurred in a non-HIV patient withFIG. 2. Bronchoalveolar lavage
(BAL) smear, BAL and blood culture
showing Talaromyces marneffei. (a)
Bronchoalveolar lavage smear
showing some intracellular yeastlike
cells in macrophages (arrow), with
characteristic septate forms (Wright
stain; original magniﬁcation, ×1000).
A high-resolution version of this slide
for use with the Virtual Microscope
is available as eSlide VM00734. (b)
BAL and blood culture at 25°C on
Sabouraud dextrose agar plate yiel-
ded fungal colonies with distinctive
red diffusible pigment.
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with large accumulated doses of steroids. We presumed that his
T. marneffei infection was related to his immunocompromised
condition, the result of his use of these immunosuppressive
agents and the moist environment of the concurrent rainy sea-
son. However, the number of doses of prednisone equivalentslf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 14–16
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16 New Microbes and New Infections, Volume 8 Number C, November 2015 NMNIthat were required for the infection to appear and why the pa-
tient’s immunity tests were not abnormal under his immuno-
compromised condition need further investigation.
Unlike cases occurring in HIV patients, our patient with
T. marneffei infection had lungs that were seriously impaired
and presented with a signiﬁcant adult respiratory distress
syndrome. However, he had no skin lesions, lymphadenopa-
thies or any opportunistic infections. Instead, the patient’s
pulmonary images indicated rare diffuse interstitial and mul-
tiple cavitary lung lesions, comparable to those in a previous
report by Hung et al. of a cavitary T. marneffei (Penicillium
marneffei) pneumonia in an HIV patient [6]. Our patient
received a combination of liposomal amphotericin B and
itraconazole for a longer period than suggested in reference
guidelines as an initial treatment because of his severe con-
dition, and he responded well in spite of some adverse
gastrointestinal effects. Because the patient should have
recovered from his immunocompromised condition after the
glucocorticoid withdrawal, the necessity for the course of
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